+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Golimumab"

Simponi - Product Thumbnail Image

Simponi

  • Report
  • May 2018
  • 55 Pages
  • Global
From
Market Spotlight: Psoriatic Arthritis - Product Thumbnail Image

Market Spotlight: Psoriatic Arthritis

  • Report
  • September 2020
  • 65 Pages
  • Global
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Psoriatic Arthritis Market and Forecast Analysis 2035 - Product Thumbnail Image

Psoriatic Arthritis Market and Forecast Analysis 2035

  • Drug Pipelines
  • July 2018
  • 503 Pages
  • Global
From
Global and Chinese Golimumab Industry, 2021 Market Research Report - Product Thumbnail Image

Global and Chinese Golimumab Industry, 2021 Market Research Report

  • Report
  • January 2021
  • 140 Pages
  • China, Global
From
Loading Indicator

Golimumab is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Golimumab is administered as an intravenous infusion or subcutaneous injection. Golimumab is one of several drugs used to treat immune disorders. Other drugs used to treat these conditions include biologics such as adalimumab, etanercept, and infliximab, as well as non-biologic drugs such as methotrexate and corticosteroids. Golimumab is marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Other companies in the market include AbbVie, Amgen, and Pfizer. Show Less Read more